| 摘要 |
Use of 2-methyl-1-(1-piperidinyl)- 1-(2-thienyl) cyclohexane (I) in racemic, diasteroisomeric or enantiomeric form, in pharmaceutical compositions to limit or inhibit the effects of neurotoxic compounds or those containing neurotoxin, is new. (I) is preferably used with >= 1 anticholinergic, anticonvulsant or cholinesterase reactivator. Suitable anticholinergics are atropine, scopolamine, atropine N-oxide, dihexyverine, and tiemonium methyl sulphate. Suitable anticonvulsants include phenobarbital, primidone, benzodiazepines, carbamazepine, ethosuximide, phenytoine, sodium valproate, progabide, gabapentine, vigabatrine, and loprazolam. Suitable cholinesterase reactivators are pralidoxime, obidoxime and HI6. A reversible cholinesterase inhibitor may also be included, such as pyridostigmine or physostigmine. Use of 2-methyl-1-(1-piperidinyl)- 1-(2-thienyl) cyclohexane (I) in racemic, diasteroisomeric or enantiomeric form, in pharmaceutical compositions to limit or inhibit the effects of neurotoxic compounds or those containing neurotoxin, is new. |
